May 27, 2019 / 5:00 AM / 6 months ago

Swiss stocks - Factors to watch on May 27

ZURICH/BERLIN, May 27 (Reuters) - The Swiss blue-chip SMI was seen opening 0.4 percent higher at 9,701 points on Monday, according to premarket indications by bank Julius Baer .

Here are some of the main factors that may affect Swiss stocks:


The drugmaker on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the one-time treatment at a record $2.125 million.

Separately, Novartis’ breast cancer treatment alpslisib, to be marketed under the brand name Piqray, also won FDA approval on Friday.


The Swatch Group - 8.00 CHF/shr dividend


* Medartis said it has named a new CEO, Cristoph Broennimann

* DKSH Holding said it bought a specialty chemicals distributor in Benelux

* Santhera said it has submitted a marketing authorization application for Puldysa for respiratory dysfunction in patients with Duchenne muscular dystrophy to the European Medicines Agency.

* Aevis Victoria said it placed 61% of Infracore’s share capital


Non-farm payrolls for the first quarter due at 0630 GMT. (Reporting by Zurich newsroom and Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below